BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yamashita Y, Tsujino I, Sato T, Yamada A, Watanabe T, Ohira H, Nishimura M. Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension. World J Hepatol 2014; 6(11): 825-829 [PMID: 25429321 DOI: 10.4254/wjh.v6.i11.825]
URL: https://www.wjgnet.com/1948-5182/full/v6/i11/825.htm
Number Citing Articles
1
Lynn A. Fussner, Michael J. Krowka. Current Approach to the Diagnosis and Management of Portopulmonary HypertensionCurrent Gastroenterology Reports 2016; 18(6) doi: 10.1007/s11894-016-0504-2
2
M. Cataldi, A. Cavaccini. Reference Module in Biomedical Sciences2017;  doi: 10.1016/B978-0-12-801238-3.99354-1
3
Masanori Atsukawa, Masashi Takano, Junichi Omura. Treatment pattern and clinical outcomes in portopulmonary hypertension: A database study in JapanJGH Open 2022; 6(11): 763 doi: 10.1002/jgh3.12820
4
Arun Jose, Shimul A. Shah, Chandrashekar J. Gandhi, Francis X. McCormack, Jean M. Elwing. Orphan Lung Diseases2023; : 177 doi: 10.1007/978-3-031-12950-6_11
5
Michael McGee, Nicholas Whitehead, Scott Twaddell, Nicholas Collins. Pulmonary hypertension in patients with a history of intravenous drug useCurrent Medical Research and Opinion 2019; 35(6): 1097 doi: 10.1080/03007995.2018.1558863